James Karrels
Net Worth

Last updated:

What is James Karrels net worth?

The estimated net worth of Mr. James Karrels is at least $7,626,133 as of 4 Mar 2024. He owns shares worth $258,893 as insider, has earned $615,000 from insider trading and has received compensation worth at least $6,752,240 in MacroGenics, Inc..

What is the salary of James Karrels?

Mr. James Karrels salary is $613,840 per year as Senior Vice President, Chief Financial Officer & Corporation Sec. in MacroGenics, Inc..

How old is James Karrels?

Mr. James Karrels is 58 years old, born in 1967.

What stocks does James Karrels currently own?

As insider, Mr. James Karrels owns shares in one company:

Company Title Shares Price per share Total value
MacroGenics, Inc. (MGNX) Senior Vice President, Chief Financial Officer & Corporation Sec. 171,452 $1.51 $258,893

What does MacroGenics, Inc. do?

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX logo
MGNX
MacroGenics, Inc.
$1.51

James Karrels insider trading

MacroGenics, Inc.

Mr. James Karrels has made 3 insider trades between 2014-2024, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of MGNX stock worth $615,000 on 4 Mar 2024.

The largest trade he's ever made was exercising 40,000 units of MGNX stock on 15 Jun 2022. As of 4 Mar 2024 he still owns at least 171,452 units of MGNX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 30,000 $20.5 $615,000
Option
Restricted Stock Unit 15,003 N/A N/A
Option
Common Stock 15,003 N/A N/A
Purchase
Common Stock 40,000 $2.47 $98,800
Option
Employee stock option (right to buy) 8,316 $1.51 $12,557
Option
Common Stock 8,316 $1.51 $12,557
Sale
Common Stock 15,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Employee stock option (right to buy) 6,000 N/A N/A
Option
Employee stock option (right to buy) 6,000 $0.76 $4,530
Option
Common Stock 6,000 $1.23 $7,350
Option
Employee stock option (right to buy) 4,473 N/A N/A
Option
Common Stock 4,473 N/A N/A
Option
Employee stock option (right to buy) 12,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Option
Employee stock option (right to buy) 7,326 N/A N/A
Option
Common Stock 7,326 N/A N/A
Option
Employee stock option (right to buy) 7,326 $0.94 $6,886
Option
Employee stock option (right to buy) 5,314 N/A N/A
Option
Common Stock 5,314 N/A N/A
Option
Employee stock option (right to buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Employee stock option (right to buy) 3,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Employee stock option (right to buy) 6,516 N/A N/A
Option
Common Stock 6,516 N/A N/A
Option
Employee stock option (right to buy) 3,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Employee stock option (right to buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Employee stock option (right to buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Employee Stock Option (right to buy) 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Employee Stock Option (right to buy) 4,100 N/A N/A
Option
Common Stock 4,100 N/A N/A

MacroGenics key executives

MacroGenics, Inc. executives and other stock owners filed with the SEC: